Profile data is unavailable for this security.
About the company
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-13.07m
- Incorporated2017
- Employees4.00
- LocationCNS Pharmaceuticals Inc2100 West Loop S Ste 900HOUSTON 77027-3522United StatesUSA
- Websitehttps://cnspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agentix Corp | 0.00 | -655.59k | 1.68m | -- | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0853 | 0.00 | -- | -- | -- | -746.86 | -- | -- | -- | -- | -- | -- | -- | -- | -7.07 | -- | -- | -- | -- | 3.09 | -- | -- | -- |
| Clearmind Medicine Inc | 0.00 | -3.86m | 1.81m | -- | -- | 0.1604 | -- | -- | -30.64 | -30.64 | 0.00 | 7.54 | 0.00 | -- | -- | -- | -57.83 | -128.70 | -178.71 | -360.04 | -- | -- | -- | -- | -- | -- | 0.5987 | -- | -- | -- | 26.60 | -- | -- | -- |
| Azitra Inc | 0.00 | -11.12m | 1.82m | 12.00 | -- | 0.4156 | -- | -- | -5.49 | -5.49 | 0.00 | 0.4066 | 0.00 | -- | -- | 0.00 | -157.91 | -- | -203.88 | -- | -- | -- | -- | -- | -- | -- | 0.1197 | -- | -98.91 | -- | 29.05 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -20.07m | 1.91m | 7.00 | -- | 0.2985 | -- | -- | -134.42 | -134.42 | 0.00 | 9.01 | 0.00 | -- | -- | 0.00 | -103.46 | -70.71 | -124.04 | -82.92 | -- | -- | -- | -12,694.84 | -- | -- | 0.0028 | -- | -- | -- | -110.38 | -- | 119.51 | -- |
| Yubo International Biotech Ltd | -20.00 | -1.23m | 1.96m | 18.00 | -- | -- | -- | -- | -0.0099 | -0.0099 | 0.00 | -0.0098 | -0.00002 | -0.0005 | -- | -1.11 | -105.87 | -- | -- | -- | -- | -- | -- | -- | 0.2394 | -- | -- | -- | -99.43 | -- | -48.55 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -3.95m | 2.01m | 2.00 | -- | 0.3342 | -- | -- | -7.30 | -7.30 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -75.76 | -86.22 | -80.46 | -561.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.15 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -13.07m | 2.02m | 4.00 | -- | 0.189 | -- | -- | -130.83 | -130.83 | 0.00 | 17.25 | 0.00 | -- | -- | 0.00 | -135.60 | -153.00 | -197.11 | -237.57 | -- | -- | -- | -- | -- | -- | 0.0031 | -- | -- | -- | 21.18 | -- | -26.93 | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 2.02m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| CDT Equity Inc | 0.00 | -20.70m | 2.03m | 6.00 | -- | 0.3282 | -- | -- | -473.79 | -473.79 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -358.56 | -- | -- | -- | -- | -- | -- | -- | -- | -16.00 | 0.2881 | -- | -- | -- | -3,227.48 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 2.17m | 13.00 | -- | 0.2579 | -- | 137.62 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -12.49m | 2.28m | 5.00 | -- | -- | -- | -- | -20.88 | -20.88 | 0.00 | -0.407 | 0.00 | -- | -- | 0.00 | -219.08 | -- | -427.33 | -- | -- | -- | -- | -- | -- | -91.40 | 3.62 | -- | -- | -- | -5.78 | -- | -- | -- |
| Purminds Enterprises Inc | 0.00 | -77.46k | 2.36m | 0.00 | -- | 0.0654 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.40m | 30.00 | -- | -- | -- | 3.99 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| BioRestorative Therapies Inc | 383.40k | -12.67m | 2.42m | 11.00 | -- | 0.9713 | -- | 6.30 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
Data as of Feb 17 2026. Currency figures normalised to CNS Pharmaceuticals Inc's reporting currency: US Dollar USD
10.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Stonepine Capital Management LLCas of 31 Dec 2025 | 48.83k | 7.87% |
| DRW Securities LLCas of 31 Dec 2025 | 15.43k | 2.49% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 416.00 | 0.07% |
| UBS Securities LLCas of 31 Dec 2025 | 195.00 | 0.03% |
| Sound Income Strategies LLCas of 31 Dec 2025 | 16.00 | 0.00% |
| Barrett & Co., Inc.as of 31 Dec 2025 | 8.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 4.00 | 0.00% |
| MAI Capital Management LLCas of 31 Dec 2025 | 3.00 | 0.00% |
| Danske Bank A/S (Investment Management)as of 31 Dec 2025 | 1.00 | 0.00% |
| Tower Research Capital LLCas of 30 Sep 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
